左卡尼汀联合辅酶Q10治疗重症慢性心力衰竭的临床疗效及安全性  

Clinical efficacy and safety of L-carnitine combined with coenzyme Q10 in the treatment of severe chronic heart failure

作　　者：王敬怡 WANG Jing-yi(Intensive Care Department,Xinmin People's Hospital,Xinmin 110300,China)

机构地区：[1]辽宁省新民市人民医院重症监护科,110300

出　　处：《中国实用医药》2023年第10期101-103,共3页China Practical Medicine

摘　　要：目的 观察左卡尼汀联合辅酶Q10治疗重症慢性心力衰竭(CHF)的疗效及安全性。方法 76例重症CHF患者,应用随机数字表法分为对照组及试验组,每组38例。对照组接受左卡尼汀治疗,试验组接受左卡尼汀联合辅酶Q10治疗。比较两组临床疗效,治疗前后的血管活性指标[血管紧张素Ⅱ(AngⅡ)、血栓素B_(2)(TXB_(2))、内皮素-1(ET-1)、一氧化氮(NO)]水平,不良反应发生情况。结果 试验组临床总有效率为97.37%,高于对照组的84.21%,差异具有统计学意义(P<0.05)。治疗后,两组的AngⅡ、TXB_(2)、ET-1水平低于本组治疗前,NO水平高于本组治疗前,且试验组的AngⅡ(35.24±5.47)pg/ml、TXB_(2)(22.17±3.16)pg/ml、ET-1(50.89±7.26)pg/ml低于对照组的(38.02±5.72)、(24.61±3.15)、(54.35±7.17)pg/ml,NO(85.46±9.08)μmol/L高于对照组的(80.27±9.41)μmol/L,差异具有统计学意义(P<0.05)。试验组不良反应发生率为2.63%,低于对照组的15.79%,差异具有统计学意义(P<0.05)。结论 予以重症CHF患者左卡尼汀联合辅酶Q10治疗存在理想价值,可优化血管活性,且不良反应较少,值得临床借鉴。Objective To observe the efficacy and safety of L-carnitine combined with coenzyme Q10 in the treatment of severe chronic heart failure(CHF).Methods A total of 76 patients with severe CHF were divided into control group and experimental group according to the random numerical table,with 38 cases in each group.The control group was treated with L-carnitine,and the experimental group was treated with L-carnitine and coenzyme Q10.Both groups were compared in terms of clinical efficacy,vascular activity index[angiotensinⅡ(AngⅡ),thromboxin B2(TXB2),endothelin-1(ET-1),nitric oxide(NO)]levels before and after treatment,and the occurrence of adverse reactions.Results The total clinical effective rate of the experimental group was 97.37%,which was higher than that of 84.21%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of AngⅡ,TXB_(2) and ET-1 in the two groups were lower than before treatment in this group,while the level of NO was higher than that before treatment in this group;the experimental group had AngⅡof(35.24±5.47)pg/ml,TXB_(2) of(22.17±3.16)pg/ml and ET-1 of(50.89±7.26)pg/ml,which were lower than those of(38.02±5.72),(24.61±3.15)and(54.35±7.17)pg/ml in the control group;NO of(85.46±9.08)μmol/L in the experimental group was higher than that of(80.27±9.41)μmol/L in the control group;the differences were statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was 2.63%,which was lower than that of 15.79%in the control group,and the difference was statistically significant(P<0.05).Conclusion The combination of L-carnitine and coenzyme Q10 has ideal value in the treatment of severe CHF patients,which can optimize vascular activity and has fewer adverse reactions,which is worthy of clinical reference.

关 键 词：左卡尼汀 辅酶Q10 重症慢性心力衰竭 临床疗效 安全性 

分 类 号：R541.6[医药卫生—心血管疾病]